Harnessing the therapeutic potential of host antiviral restriction factors that target HIV

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 1, 2013, Pages 1-4

  Sloan, Richard D ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

antiviral therapy; APOBEC3G; HIV; restriction factors; tetherin

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; INTERFERON; MEMBRANE PROTEIN; TETHERIN PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; DISEASE ASSOCIATION; DRUG EFFECT; GENE PRODUCT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TREATMENT PLANNING; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD; CARRIER PROTEINS; CYTIDINE DEAMINASE; GENE PRODUCTS, VIF; GENE TARGETING; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTAGENESIS; VIRUS REPLICATION;

EID: 84871947792     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.146     Document Type: Review

References (25)

1. Bushman FD, Malani N, Fernandes J et al. Host cell factors in HIV replication: Meta-analysis of genome-wide studies. PLoS Pathog. 5(5), e1000437 (2009).
2. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2(5), a006940 (2012).
3. Pillai SK, Abdel-Mohsen M, Guatelli J et al.; Swiss HIV Cohort Study. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo. Proc. Natl Acad. Sci. USA 109(8), 3035-3040 (2012).
4. Hultquist JF, Harris RS. Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol. 4(6), 605 (2009).
5. Nathans R, Cao H, Sharova N et al. Smallmolecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26(10), 1187-1192 (2008).
6. Cen S, Peng ZG, Li XY et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285(22), 16546-16552 (2010).
7. Berkhout B, de Ronde A. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18(13), 1861-1863 (2004). (Pubitemid 39179645)
8. Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84(14), 7396-7404 (2010).
9. Li M, Shandilya SM, Carpenter MA et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7(3), 506-517 (2012).
10. Kim EY, Bhattacharya T, Kunstman K et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J. Virol. 84(19), 10402-10405 (2010).
11. Fourati S, Malet I, Lambert S et al. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 26(13), 1619-1624 (2012).
12. Jern P, Russell RA, Pathak VK, Coffin JM. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5(4), e1000367 (2009).
13. Montal M. Vpu matchmakers as a therapeutic strategy for HIV infection. PLoS Pathog. 5(5), e1000246 (2009).
14. Zhang Q, Liu Z, Mi Z et al. Highthroughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2. Antiviral Res. 91(3), 321-329 (2011).
15. Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J. Antiviral efficacy of the novel compound BIT225 against HIV1 release from human macrophages. Antimicrob. Agents Chemother. 54(2), 835-845 (2010).
16. Kuhl BD, Cheng V, Donahue DA et al. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism. PLoS ONE 6(11), e27660 (2011).
17. Price AJ, Marzetta F, Lammers M et al. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat. Struct. Mol. Biol. 16(10), 1036-1042 (2009).
18. Caines ME, Bichel K, Price AJ et al. Diverse HIV viruses are targeted by a conformationally dynamic antiviral. Nat. Struct. Mol. Biol. 19(4), 411-416 (2012).
19. Neagu MR, Ziegler P, Pertel T et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119(10), 3035-3047 (2009).
20. Shi J, Zhou J, Shah VB, et al. Smallmolecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85(1), 542-549 (2011).
21. Christ F, Voet A, Marchand A et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 6(6), 442-448 (2010).
22. Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics. Expert Rev. Mol. Med. 12, e4 (2010).
23. Brass AL, Huang IC, Benita Y et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139(7), 1243-1254 (2009).
24. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85(5), 2126-2137 (2011).
25. Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broadspectrum antiviral therapeutics. PLoS ONE 6(7), e22572 (2011).